Arndt Vogel
#153,251
Most Influential Person Now
Researcher
Arndt Vogel's AcademicInfluence.com Rankings
Arndt Vogelphilosophy Degrees
Philosophy
#8560
World Rank
#11967
Historical Rank
Logic
#5590
World Rank
#6999
Historical Rank
Download Badge
Philosophy
Why Is Arndt Vogel Influential?
(Suggest an Edit or Addition)Arndt Vogel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (2018) (2744)
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (2018) (1462)
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. (2020) (629)
- Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (2014) (513)
- A comparison of fibrosis progression in chronic liver diseases. (2003) (447)
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) (402)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (263)
- Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis (2002) (247)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (185)
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. (2016) (179)
- Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. (2008) (164)
- Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP‐glucuronosyltransferase UGT1A4 (2004) (161)
- Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. (2014) (154)
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. (2021) (141)
- Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade (2016) (141)
- MicroRNA‐221 overexpression accelerates hepatocyte proliferation during liver regeneration (2013) (140)
- Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer (2002) (139)
- UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. (2003) (136)
- Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. (2001) (130)
- Long‐term outcome of liver transplantation for autoimmune hepatitis (2004) (130)
- A Direct In Vivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration (2013) (130)
- Loss of Imprinting and Allelic Switching at the DLK1-MEG3 Locus in Human Hepatocellular Carcinoma (2012) (126)
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. (2019) (120)
- The genetic background of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy and its autoimmune disease components (2002) (119)
- Epidemiology and Risk Factors of Cholangiocarcinoma (2016) (110)
- Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice (2014) (106)
- Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management (2019) (104)
- Prediction of short‐ and long‐term outcome in patients with autoimmune hepatitis (2015) (104)
- The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI (2017) (102)
- Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells (2009) (101)
- Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation‐associated liver carcinogenesis in mice (2013) (94)
- Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis (2018) (93)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. (2020) (92)
- Autoimmune hepatitis, from mechanisms to therapy (2006) (91)
- Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. (2014) (91)
- Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort (2019) (89)
- Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. (2019) (89)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (87)
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022) (86)
- Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. (2011) (84)
- Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. (2017) (84)
- Incidence and long‐term risk of de novo malignancies after liver transplantation with implications for prevention and detection (2013) (84)
- Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). (2017) (82)
- The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice (2013) (81)
- Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol‐related cirrhosis (2018) (79)
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. (2019) (76)
- Nrf2 Activates Augmenter of Liver Regeneration (ALR) via Antioxidant Response Element and Links Oxidative Stress to Liver Regeneration (2013) (75)
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach (2019) (75)
- Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (75)
- Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene (2005) (75)
- 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link (2003) (73)
- Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker (2013) (71)
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements (2020) (69)
- Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. (2021) (67)
- Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers (2020) (65)
- Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. (2008) (65)
- Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. (2016) (62)
- Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. (2016) (60)
- Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. (2009) (60)
- Autoimmune regulator AIRE: Evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1 (2001) (59)
- FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (2019) (59)
- Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death (2004) (58)
- Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion (2017) (57)
- Autoimmunity and hepatitis C. (2003) (57)
- TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice (2020) (56)
- A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. (2014) (54)
- Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis (2018) (53)
- PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. (2018) (52)
- Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial (2020) (52)
- Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma (2019) (52)
- Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT1A7 in proximal digestive tract cancer. (2002) (51)
- Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC). (2016) (49)
- [Diagnosis of and therapy for hepatocellular carcinoma]. (2013) (49)
- Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience (2015) (48)
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study (2022) (46)
- Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. (2021) (46)
- Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). (2020) (46)
- p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury (2013) (45)
- Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). (2019) (44)
- Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma (2018) (43)
- Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma (2019) (43)
- Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma (2013) (42)
- Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report (2015) (41)
- EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. (2014) (40)
- The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers (2009) (39)
- Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. (2021) (39)
- Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage (2009) (39)
- Murine Embryonic Stem Cell-Derived Hepatic Progenitor Cells Engraft in Recipient Livers with Limited Capacity of Liver Tissue Formation (2008) (39)
- The C/C(-13910) and G/G(-22018) genotypes for adult-type hypolactasia are not associated with inflammatory bowel disease. (2003) (38)
- Current and novel therapeutic opportunities for systemic therapy in biliary cancer (2020) (37)
- MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. (2015) (37)
- Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study (2017) (37)
- Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma (2014) (36)
- Hepatocellular carcinoma (2022) (36)
- The diagnosis and treatment of cholangiocarcinoma. (2014) (34)
- Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells (2019) (34)
- KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. (2018) (33)
- Autoimmunity and viruses. (2002) (33)
- Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients (2013) (32)
- FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? (2020) (32)
- Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities (2020) (32)
- Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. (2006) (31)
- Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. (2018) (30)
- Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival (2018) (30)
- A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. (2015) (29)
- The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis (2017) (29)
- The Pathogenesis of Hepatocellular Carcinoma (2014) (29)
- mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. (2012) (29)
- Activation of nuclear factor E2‐related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development (2008) (29)
- Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab (2021) (28)
- Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. (2021) (28)
- HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection (2018) (28)
- Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. (2021) (28)
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. (2020) (27)
- Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. (2015) (27)
- Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 (2020) (26)
- Diagnostik und Therapie des hepatozellulären Karzinoms (2013) (26)
- Combination of Conservative and Interventional Therapy Strategies for Intra- and Extrahepatic Cholangiocellular Carcinoma: A Retrospective Survival Analysis (2011) (26)
- Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. (2016) (26)
- Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine (2015) (25)
- Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis (2021) (25)
- Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 (2020) (25)
- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial (2016) (25)
- The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma (2021) (25)
- Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors (2017) (24)
- Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization (2017) (24)
- Surveillance in cholangiocellular carcinoma. (2016) (24)
- The BH3-only protein bid does not mediate death-receptor-induced liver injury in obstructive cholestasis. (2009) (24)
- Second‐line chemotherapy in biliary tract cancer: Outcome and prognostic factors (2019) (24)
- Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro (2019) (23)
- Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT) (2016) (23)
- Risk estimation for biliary tract cancer: Development and validation of a prognostic score (2017) (22)
- Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study (2021) (22)
- Preferences of colorectal cancer patients for treatment and decision-making: a systematic literature review. (2014) (22)
- Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. (2015) (22)
- Immunotherapies in clinical development for biliary tract cancer (2020) (21)
- Murine embryonic stem cell-derived hepatic progenitor cells engraft in recipient livers with limited capacity of liver tissue formation. (2008) (21)
- Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (21)
- Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review (2016) (21)
- The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies (2019) (20)
- A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). (2017) (20)
- hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma (2017) (20)
- Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. (2016) (19)
- Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease (2018) (19)
- “CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO. (2017) (19)
- Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma (2018) (18)
- Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience (2022) (18)
- Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie). (2015) (18)
- Therapy preferences of patients with lung and colon cancer: a discrete choice experiment (2017) (18)
- Hepatocyte-specific S100a8 and S100a9 transgene expression in mice causes Cxcl1 induction and systemic neutrophil enrichment (2012) (17)
- Sequential systemic treatment in patients with hepatocellular carcinoma (2020) (17)
- Meetings and Conferences · Tagungen und Kongresse (2000) (17)
- Systemic therapy of advanced hepatocellular carcinoma. (2020) (17)
- IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. (2021) (17)
- Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma (2020) (17)
- ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation. (2017) (17)
- Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice (2017) (16)
- Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2015) (16)
- LBA30Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) (2017) (16)
- Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival (2015) (16)
- Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). (2020) (16)
- Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma (2018) (16)
- Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center (2017) (16)
- Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads (2018) (15)
- Application of patient derived liver cancer cell lines for phenotypic characterization and therapeutic target identification (2018) (15)
- Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma (2021) (15)
- Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. (2007) (15)
- Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. (2021) (15)
- The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis (2020) (15)
- The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation (2021) (14)
- Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events (2015) (14)
- Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization (2017) (14)
- Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. (2017) (14)
- FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. (2020) (14)
- Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC) (2020) (13)
- Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). (2020) (13)
- Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study (2022) (13)
- Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE (2016) (13)
- Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER). (2017) (13)
- Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury (2020) (13)
- A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. (2018) (13)
- Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. (2019) (13)
- Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC (2018) (12)
- Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. (2001) (12)
- Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies (2020) (12)
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. (2022) (12)
- MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology (2016) (12)
- Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1. (2017) (11)
- Genotyping of the UDP-glucuronosyltransferase (UGT) 1A7 gene revisited. (2011) (11)
- Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (2022) (11)
- Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. (2017) (11)
- Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. (2021) (11)
- A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 (2019) (10)
- Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial (2022) (10)
- Advances in systemic therapy for the first-line treatment of unresectable HCC (2021) (10)
- Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9 (2015) (10)
- First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. (2014) (10)
- Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. (2018) (10)
- Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer (2019) (10)
- LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype (2019) (10)
- Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery (2020) (9)
- Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma (2021) (9)
- Autoimmune hepatitis and overlap syndromes (2002) (9)
- CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209). (2017) (9)
- Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter (2019) (9)
- Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma Chemosaturation durch perkutane hepatische Perfusion mit Melphalan bei hepatisch metastasiertem Aderhautmelanom: eine Überlebens- und Sicherheitsanalyse (2021) (9)
- 78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer (2020) (9)
- The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma (2021) (9)
- IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL TATA BOX POLYMORPHISM OF THE UDP GLUCURONOSYLTRANSFERASE 1 A 7 GENE (2005) (9)
- Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets (2018) (8)
- 45P Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs (2020) (8)
- The BH3‐only protein BID impairs the p38‐mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice (2015) (8)
- Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience (2021) (8)
- Next-Generation Biomarkers for Cholangiocarcinoma (2021) (8)
- Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). (2003) (8)
- 618OHealth-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR) (2017) (8)
- Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab (2021) (8)
- Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study (2022) (8)
- Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial. (2017) (8)
- Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). (2021) (8)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (7)
- Health-Related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR) (2017) (7)
- Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis? (2021) (7)
- ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation. (2018) (7)
- P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (2020) (7)
- Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma (2022) (7)
- A novel AIRE mutation in an APECED patient with candidiasis, adrenal failure, hepatitis, diabetes mellitus and osteosclerosis. (2003) (6)
- PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (6)
- Abstract CT284: Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation (2020) (6)
- A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). (2017) (6)
- 322 SHOULD ALL PATIENTS WITH AUTOIMMUNE HEPATITIS BE SCREENED FOR HEV-INFECTION? (2010) (6)
- UGT1A7 polymorphisms, polycyclic aromatic hydrocarbons and the development of hepatocellular cancer (2004) (6)
- The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021) (6)
- Multimodale Therapie des hepatozellulären Karzinoms (2010) (5)
- Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice (2019) (5)
- Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. (2022) (5)
- Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads (2019) (5)
- Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study. (2021) (5)
- Medical therapy of HCC. (2021) (5)
- 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment (2020) (5)
- Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement. (2019) (5)
- First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials (2018) (5)
- ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240 (2021) (5)
- Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy. (2001) (5)
- Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug? (2020) (5)
- Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma (2019) (5)
- Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry (2020) (5)
- S3-Leitlinie Diagnostik und Therapie biliärer Karzinome (2022) (5)
- The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective (2021) (5)
- Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis. (2020) (5)
- Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing. (2020) (5)
- Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing (2022) (4)
- Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab (2022) (4)
- Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510 (2021) (4)
- Current and Future Systemic Therapies in Biliary Tract Cancer. (2021) (4)
- Evaluation of a Motion Correction Algorithm for C-Arm Computed Tomography Acquired During Transarterial Chemoembolization (2020) (4)
- Is There Any Evidence for a Role of Local Treatment in Cholangiocarcinoma? (2014) (4)
- Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. (2020) (4)
- Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma (2017) (4)
- 1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation (2020) (4)
- Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis (2022) (4)
- Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research (2019) (4)
- Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial (2016) (4)
- LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) (2021) (4)
- Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study (2019) (4)
- FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA) (2016) (3)
- ASCO- und ESMO-Update 2017 – Neuigkeiten vom 53. Meeting der American Society of Clinical Oncology/ASCO 2017 und European Society for Medical Oncology/ESMO-Congress 2017 (2018) (3)
- Potential viral triggers for pediatric and adult autoimmune hepatitis (2017) (3)
- Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. (2022) (3)
- Serological diagnosis of early HCC in NASH: A German multicenter study (2018) (3)
- [The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk assessment]. (2021) (3)
- BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options (2021) (3)
- Role of recombinant hirudin in a pig-to-human lung transplantation model. (2002) (3)
- FGFR2 Inhibition in Cholangiocarcinoma. (2022) (3)
- Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE (2018) (3)
- 670PA randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC) (2017) (3)
- Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis. (2022) (3)
- p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model (2021) (3)
- ASCO-Update 2015 – Neuigkeiten vom 51. Meeting der American Society of Clinical Oncology/ASCO 2015 (2004) (3)
- Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. (2021) (3)
- OWE-016 Genetic variants in PNPLA3 and TM6SF2 predispose to hepatocellular carcinoma in patients with alcohol-related cirrhosis (2018) (3)
- Immunopathogenesis of Extrahepatic Manifestations in HAV, HBV, and HCV Infections (2007) (3)
- 2358 Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial (2015) (3)
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma. (2014) (3)
- S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome (2022) (2)
- Hyperkeratoses as paraneoplastic syndrome (2012) (2)
- Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (2022) (2)
- 988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC (2020) (2)
- Endoscopic biliary drainage in patients with cholangiocarcinoma – self-expanding metal versus polyethylene stents (2019) (2)
- Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis (2022) (2)
- Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. (2021) (2)
- RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). (2020) (2)
- Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. (2023) (2)
- Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function (2022) (2)
- Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program. (2018) (2)
- Corrigendum to "Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma" [Cancer Treatm. Rev. 82 (2019) 101946]. (2019) (2)
- Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. (2022) (2)
- Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis (2017) (2)
- Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis (2017) (2)
- Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study (2017) (2)
- Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC). (2020) (2)
- SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response (2021) (2)
- Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers. (2016) (2)
- Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC (2016) (2)
- Interferon-free cure of hepatitis C virus infection does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis (2017) (2)
- Randomisierte Phase-IIb-Studie mit Pexa-Vec (pexastimogene devacirepvec; JX-594), eine onkolytische Immuntherapie mit Best Supportive Care (BSC) gegen BSC allein bei Patienten mit Leberzellkarzinom (HCC) und fehlgeschlagener Sorafenib-Behandlung (TRAVERSE) (2015) (1)
- Autoimmunhepatitis : Diagnostik und Therapie (Schwerpunkt) (2009) (1)
- Molekulares Tumorboard: Cholangiokarzinom (2019) (1)
- Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study (2020) (1)
- The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI (2017) (1)
- State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post‐liver transplantation and resection (2021) (1)
- Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells (2022) (1)
- Genetische Varianten der UDP-Glukuronosyltransferase UGT1A7 bei entzündlichen Darmerkrankungen (2004) (1)
- Application of Patient-Derived Liver Cancer Cells in Personalized Treatment Approach: Phenotypic Characterization and Therapeutic Target Identification (2018) (1)
- Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy (2021) (1)
- Transarterial Chemoembolization versus Resection in Patients with Large, Solitary Hepatocellular Carcinoma. (2016) (1)
- Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. (2022) (1)
- 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study (2021) (1)
- The strength of the Fas ligand signal determines whether hepatocytes act as type-1 or type-2 cells in murine livers (2010) (1)
- Study protocol: the OptiScreen-Study: optimized psycho-oncological care—from screening to intervention (2022) (1)
- Immunotherapy: New Options in Gastrointestinal Cancers? (2019) (1)
- Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power) (2019) (1)
- Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433]. (2022) (1)
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
- Von der zielgerichteten zur immunonkologischen Systemtherapie (2022) (1)
- Prognostische Faktoren bei Patienten mit cholangiozellulärem Karzinom – monozentrische Analyse von 570 Patienten (2013) (1)
- 788 Effect of Genetic Ablation of the Acid/Base Transporters PNBC1, NHE1, NHE2, and Slc26a7, On Gastric Epithelial Functions (2009) (1)
- Real-life results from the prospective QoliXane trial of the platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry. (2020) (1)
- Hepatocyte-specific S100a8 and S100a9 transgene expression in mice causes Cxcl1 induction and systemic neutrophil enrichment (2012) (1)
- Carriage of HSD17B13 rs72613567TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (1)
- Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2) (2019) (1)
- Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. (2022) (1)
- 673 PROGNOSTIC FACTORS IN PATIENTS WITH CHOLANGIOCELLULAR CARCINOMA – COMPREHENSIVE ANALYSIS OF 570 PATIENTS (2013) (1)
- P396 PREDICTION OF SHORT- AND LONG-TERM OUTCOME IN PATIENTS WITH AUTOIMMUNE HEPATITIS (2014) (1)
- Searching high and low: Cancer stem cells in the eye (2008) (1)
- Mimics of Autoimmune Hepatitis: Drug Induced and Immune Mediated Liver Disease (2012) (1)
- P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation (2021) (1)
- The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC). (2021) (1)
- Identification of two functional polymorphisms of the human hepatic Ugtla4 gene: Implications for drug therapy and genetic disease predisposition (2003) (1)
- 1077 NRF2, A TRANSCRIPTION FACTOR MAINLY INVOLVED IN ANTIOXIDANT DEFENSE, REGULATES THE EXPRESSION OF ALR AUGMENTER OF LIVER REGENERATION (2011) (1)
- Incidence and Prognosis of de Novo Malignancies after Liver Transplantation: 2033 (2012) (1)
- Current and novel therapeutic opportunities for systemic therapy in biliary cancer (2020) (1)
- High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy (2021) (1)
- Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study (2022) (1)
- 1525O The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry (2020) (1)
- Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC). (2019) (1)
- LBA-007FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis. (2017) (1)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (1)
- Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study (2022) (1)
- Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy (2021) (1)
- FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis. (2017) (1)
- Vitamin D receptor polymorphisms and susceptibility to autoimmune liver diseases (2002) (1)
- 1871TiP PLATON – “Platform for Analyzing Targetable Tumor Mutations”: A pilot study (2021) (1)
- 238 High frequency of single nucleotide polymorphisms (SNPS) at the human UGT1A gene locus: differential alterations of glucuronidation of two novel SNPS of the hepatic UGT1A4 gene (2003) (1)
- 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240 (2020) (1)
- Chemosaturation durch perkutane hepatische Perfusion mit Melphalan bei hepatisch metastasiertem Aderhautmelanom: eine Überlebens- und Sicherheitsanalyse (2021) (1)
- P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib (2021) (1)
- P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC (2021) (1)
- Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial. (2017) (1)
- Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial. (2014) (1)
- Targeted therapies in cholangiocarcinoma: Assessment of US oncologist practice patterns. (2021) (1)
- Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study. (2022) (0)
- 680 NVP BEZ235-AN ALONE OR IN COMBINATION WITH CHEMOTHERAPY EFFECTIVELY INHIBITS HEPATOCELLULAR CARCINOMA GROWTH (2011) (0)
- Effects of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 on HCC (2013) (0)
- 301 RAGE IS REQUIRED FOR OVAL CELL ACTIVATION AND INFLAMMATION-ASSOCIATED MOUSE LIVER CARCINOGENESIS (2012) (0)
- Quality of life — An essential aspect in the follow-up care of patients with breast cancer (1998) (0)
- Prognostic Factors in Patients with Cholangiocellular Carcinoma – Comprehensive Analysis of 517 Patients (2013) (0)
- Activation of Nrf–2 in hereditary tyrosinemia type 1 and its role in survival and hepatocarcinogenesis (2008) (0)
- Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. (2022) (0)
- P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer (2021) (0)
- Safety and efficacy of percutaneous hepatic perfusion (Chemosaturation) in patients with primary or secondary liver tumors: a single-center experience after 54 treatments in 29 Patients (2017) (0)
- Epidemiology and Risk Factors (2013) (0)
- Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: a single-centre experience after 54 treatments (2017) (0)
- 1057 ANTI-TUMOR ACTIVITY OF THE mTOR INHIBITOR RAD001, THE DUAL mTOR/PI3-KINASE INHIBITOR BEZ235 AND THE PI3-KINASE INHIBITOR BKM120 CORRELATES WITH IMPAIRMENT OF OXIDATIVE PHOSPHORYLATION IN HCC (2013) (0)
- Safety of ramucirumab in patients with advanced gastric cancer in Europe and North America: A prospective observational registry. (2023) (0)
- Gastrointestinal , Hepatobiliary and Pancreatic Pathology The BH 3-Only Protein Bid Does Not Mediate Death-Receptor-Induced Liver Injury in Obstructive Cholestasis (2010) (0)
- Aktuelle Therapieoptionen beim Cholangiokarzinom (2017) (0)
- Parametric response mapping zur Verlaufsbeurteilung biphasischer CT-Untersuchungen nach transarterieller Chemoembolisation bei HCC (2015) (0)
- Nivolumab-Kombinationstherapie bei Plattenepithelkarzinomen des Ösophagus (2022) (0)
- Erratum zu: Update zur systemischen Therapie bei fortgeschrittenem hepatozellulärem Karzinom (2018) (0)
- Survival in Patients with Hepatcellular Carcinoma after Transarterial Chemoembolisation is Determined by Tumor Biology and Hepatic Function (2016) (0)
- Immungenetik und extrahepatische Manifestationen bei der Autoimmunhepatitis (2015) (0)
- Therapie des metastasierten Cholangiokarzinoms (2015) (0)
- Targeting FGFR2 in advanced cholangiocarcinoma: an interview with Arndt Vogel. (2020) (0)
- Aktuelle lokale und systemische Therapie biliärer Tumoren (2021) (0)
- Dissecting the role of the immune system in liver injury and hepatocarcinogenesis (2013) (0)
- Das intrahepatische Gallengangskarzinom – Diagnostik und Therapie (2018) (0)
- Polymorphe Varianten von Glukuronidierungsenzymen– veränderte katalytische Aktivität und subzelluläre Umverteilung (2004) (0)
- Leberfunktion und Tumorlast bestimmen das Überleben von Patienten mit intermediärem, hepatozellulärem Karzinom nach transarterieller Chemoembolisation (2015) (0)
- UGT1A7*3 Polymorphismus und hepatozelluläres Karzinom: signifikante Assoziation und methodische Aspekte der Genotypisierung (2005) (0)
- mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models. (2022) (0)
- Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma-authors' reply. (2020) (0)
- Patient-Derived cancer cell lines as a model for human liver cancer: from phenotypic characterization to therapeutic target identification (2017) (0)
- Aktuelle Therapiekonzepte und laufende Studien bei biliären Tumoren (2022) (0)
- Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. (2022) (0)
- Benigne Tumoren der Leber (2016) (0)
- Ein neuer UGT1A Promotorpolymorphismus: Klinische Relevanz für die Tumortherapie und Assoziation zwischen hepatischer und extrahepatischer Glukuronidierung (2005) (0)
- Übersicht – Systemische Therapie des hepatozellulären Karzinoms (2016) (0)
- S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion (2023) (0)
- Update zur systemischen Therapie bei fortgeschrittenem hepatozellulärem Karzinom (2018) (0)
- New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option (2022) (0)
- Funktionelle Polymorphismen der hepatischen Glucuronidierung: Verminderung der Östrogenmetabolisierung polymorpher UGT1A3-Varianten (2005) (0)
- Hohe Zahl und Prävalenz von single nucleotide polymorphisms (SNP) des humanen UGT1A-Genlokus: genetische Grundlage der Variabilität humaner Glukuronidierung (2015) (0)
- 505 RAPAMYCIN PREVENTS PROLIFERATION OF DAMAGES HEPATOCYTES DURING CHRONIC LIVER INJURY AND THEREBY LIVER TUMOR DEVELOPMENT (2009) (0)
- Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study. (0)
- Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma (2022) (0)
- Aktuelle Entwicklungen in der palliativen Therapie biliärer Tumoren (2023) (0)
- 270 BID-MEDIATED APOPTOSIS DOES NOT PLAY A ROLE IN OBSTRUCTIVE CHOLESTASIS FOLLOWING BILE DUCT LIGATION (2009) (0)
- Hepatozelluläres Karzinom (2018) (0)
- The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study (2019) (0)
- Treatment strategies in patients with hepatocellular carcinoma in a real-life cohort. (2016) (0)
- Application of patient-derived liver cancer cells for personalized treatment approach: from phenotypic characterization to therapeutic target identification (2018) (0)
- Personalisierte Therapie biliärer Karzinome (2023) (0)
- Systemische Therapie des hepatozellulären Karzinoms (2013) (0)
- Role of RAGE and its ligands S100A8/A9 in hepatocellular carcinoma onset and development (2015) (0)
- Polymorphe Varianten im PNPLA3- und TM6SF2-Gen sind mit dem Hepatozellulären Karzinom bei alkoholischer Leberzirrhose assoziiert (2017) (0)
- Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (2021) (0)
- Das intrahepatische Gallengangskarzinom – Diagnostik und Therapie (2018) (0)
- Aspirin und PIK3CA-Mutationen beim kolorektalen Karzinom (2014) (0)
- Hepatozelluläres Karzinom (2018) (0)
- Wertigkeit bildmorphologischer Parameter vor TACE als prognostische Faktoren für das Gesamtüberleben bei Patienten mit HCC (2013) (0)
- Diagnostik und Therapie bei Pankreaskarzinom und Cholangiokarzinom (2015) (0)
- Hyperkeratosen als paraneoplastisches Syndrom (2012) (0)
- ‘Potentially curative therapies’ for hepatocellular carcinoma: how many patients can actually be cured? (2023) (0)
- Autoimmunerkrankungen mit Leberbeteiligung (2006) (0)
- Identifikation einer neuen Mutation beim Crigler-Najjar Syndrom in drei Familien: Kombination von Promoter- und UGT1A1-Genpolymorphismen als Risikofaktoren (2015) (0)
- Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT. (2022) (0)
- Initiale Tumorreduktion nach RECIST als prognostischer Parameter bei hepatozellulärem Karzinom unter transarterieller Chemoembolisation (2013) (0)
- Palliative systemische Therapie des hepatozellulären Karzinoms (2019) (0)
- Genetisches Risikoprofil beim hepatozellulärem Karzinom: Rolle von CYP1A1, UDP-Glukuronosyltransferasen und HFE-Gen (2015) (0)
- Title: RAGE is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice Short title: Rage in inflammation-driven HCC (2013) (0)
- RAS-Analysen beim metastasierten kolorektalen Karzinom (2014) (0)
- Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations (2022) (0)
- Therapiealgorithmen von Patienten mit hepatozellulärem Karzinom im klinischen Alltag (2016) (0)
- Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort (2022) (0)
- Pankreas- und Cholangiokarzinom (2015) (0)
- Immunonkologie: Kein Bedarf mehr für interventionelle Radiologie? (2020) (0)
- Immunonkologie (2020) (0)
- Aktuelle Systemtherapie für fortgeschrittene biliäre Tumoren (2022) (0)
- Gallengangskarzinome (2017) (0)
- 1032 DISSECTING THE ROLE OF Chk2, p53 AND p21 FOR LIVER REGENERATION AND TUMOR DEVELOPMENT DURING CHRONIC LIVER INJURY (2013) (0)
- [Best supportive care in a young patient with locally advanced MSI-high colon cancer?] (2020) (0)
- Ein funktioneller Promoterpolymorphismus des UGT1A7-Gens verbindet den M. Gilbert mit dem Risiko bei Chemotherapie (2005) (0)
- Erkrankungen von Leber, Gallenwegen und Pankreas (2003) (0)
- FRI-483-Endoscopic biliary drainage in patients with cholangiocarcinoma: Polyethylene versus self-expanding metal stents (2019) (0)
- Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung (2021) (0)
- Akute und chronische nichtvirale Hepatitiden: Autoimmunerkrankungen, Medikamente und Toxine (2005) (0)
- Aktueller Stand der operativen Therapie des hepatobiliären Karzinoms (2022) (0)
- Evaluation der Lebensqualität nach initialer TACE bei HCC (2014) (0)
- c-Myc: zentraler Regulator für die Leberregeneration in Mäusen mit chronischer Leberschädigung (2015) (0)
- PS-138-PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort (2019) (0)
- Genetic risk profile and metabolic balance in hepatocellular carcinoma: Role of cyplal, Udp-glucuronosyltransferases and the HFE gene (2003) (0)
- Survival After Intra-Arterial Treatment for Hepatocellular Carcinoma: Impact of Liver Dysfunction and Development of a Predictive Statistical Model: an International Collaborative Project (2015) (0)
- P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement (2021) (0)
- Best supportive care bei einer jungen Patientin mit lokal fortgeschrittenem MSI-high-Kolonkarzinom? (2020) (0)
- Status quo in der Zweitlinientherapie des NSCLC und Ausblick in die Zukunft (2015) (0)
- Medikamentöse Standardtherapie des Cholangiokarzinoms und aktuelle Arzneimittelstudien (2013) (0)
- IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC). (2023) (0)
- TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice (2020) (0)
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? (2022) (0)
- Anti-angiogenics in Hepatocellular Cancer Therapy (2017) (0)
- Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. (2023) (0)
- Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer. (2022) (0)
- Nrf2, a transcription factor mainly involved in antioxidant defense, regulates the expression of ALR, Augmenter of Liver Regeneration (2011) (0)
- 108 NRF2 Prevents Alcohol Induced Fulminant Liver Injury (2008) (0)
- The clinical presentation and prognosis of patients with Congenital Hepatic Fibrosis (2013) (0)
- Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: A single-centre experience after 54 treatments. (2017) (0)
- Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case–control study (2017) (0)
- Epidemiologie und molekulare Pathogenese des hepatozellulären Karzinoms (2012) (0)
- Hepatozelluläres Karzinom: State of the Art (2009) (0)
- Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population. (2023) (0)
- Successful Liver Transplantation in Two Patients with Severe Hemophilia A (2008) (0)
- [28-year-old patient with hypokalemic paralysis]. (2002) (0)
- Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev). (2023) (0)
- Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (0)
- PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort (2019) (0)
- Nrf2 regulates antioxidative and liver regeneration promoting genes (2013) (0)
- Reply to Rizzo et al. (2021) (0)
- 537 COMBINATORIAL EFFECT OF PI3KAKTMTOR INHIBITORS WITH CYTOTOXIC DRUGS IN TREATMENT OF HEPATOCELLULAR CARCINOMA (2009) (0)
- FRI-044-PNPLA3 polymorphism is associated with disease progression in patients with autoimmune hepatitis (2019) (0)
- Abstract No. 210 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation (2021) (0)
- Loss of DNA methylation at imprinted loci is a frequent event in hepatocellular carcinoma and identifies patients with shortened survival (2015) (0)
- Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study. (2023) (0)
- Analysis of elderly patients with hepatocellular carcinoma undergoing transarterial chemoembolization in Germany (2012) (0)
- 417 LOSS OF C-MYC DOES NOT PREVENT PROLIFERATION IN HEPATOCYTES (2012) (0)
- Distinct Roles for Chk2/p53/p21 pathway in Liver Injury and Hepatocarcinogenesis (2013) (0)
- Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT) (2016) (0)
- Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry (2021) (0)
- Editorial Board / Contents / Imprint / Guidelines for Authors (2015) (0)
- Future Therapy of Cholangiocarcinoma (2016) (0)
- An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). (2021) (0)
- BRAF-V600E-Testung beim metastasierten kolorektalen Karzinom und neue, chemotherapiefreie Therapieoptionen (2021) (0)
- OP-08 Results of transarterial chemoembolisation using a low-embolic technique in patients with intermediate stage hepatocellular carcinoma (2013) (0)
- Treatment of Non-Colorectal Liver Metastases (2015) (0)
- The Dose Matters: Long-Term Immunosuppression’s Influence On De Novo Malignancy After Liver Transplantation.: Abstract# 673 (2014) (0)
- Hepatocyte-Specific SMAD7 Deletion Accelerates Den Induced Mouse Hepatocellular Carcinoma via Activation of STAT3 Signaling (2016) (0)
- P0331 : The ‘GALAD score’ for serological detection of hepatocellular carcinoma: International validation and assessment of the influence of tumour size and aetiology on model utility (2015) (0)
- Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials (2023) (0)
- Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. (2022) (0)
- Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience (2021) (0)
- Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. (2016) (0)
- OP-07 Initial RECIST tumour reduction as a prognostic parameter for transarterial chemoembolisation treatment success in patients with hepatocellular carcinoma (2013) (0)
- 1061 p21 REGULATES ACTIVATION OF LIVER PROGENITOR CELLS AND HEPATOCARCINOGENESIS IN INFLAMMATION-ASSOCIATED LIVER DISEASE (2013) (0)
- Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review (2023) (0)
- Chapter 18 – Autoimmune Hepatitis (2006) (0)
- Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. (2023) (0)
- Maligne primäre Lebertumoren (2016) (0)
- Bid-mediated apoptosis does not contribute to cholestatic liver injury following bile duct ligation (2009) (0)
- P-99 Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress (2020) (0)
- A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort (2022) (0)
- Schematic representation of the DLK1-MEG3 imprinted locus on chromosome 14q32. (2012) (0)
- Gallengangskarzinom und Klatskintumor (2016) (0)
- [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. (2021) (0)
- 59 IN VIVO RNAI SCREENING IDENTIFIES NEW REGULATORS OF LIVER REGENERATION (2011) (0)
- 1040 INTERACTION OF THE INNATE AND ADAPTIVE IMMUNE SYSTEM CONTRIBUTE TO LIVER INJURY AND HEPATOCARCINOGENESIS (2013) (0)
- Characterization and clinical correlation of the immune contexture in intrahepatic cholangiocarcinoma using multiplex immunohistochemistry (2022) (0)
- Title Page / Editorial Board / Contents / Imprint / Guidelines for Authors (2015) (0)
- Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma (2019) (0)
- Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial. (2021) (0)
- IGICS: JGA Keynote Program. The 13th International Gastrointestinal Consensus Symposium (GICS). Gastrointestinal Disease: From Basics to Translational and Clinical Research: Abstracts (2020) (0)
- Liver Cancer Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma (2018) (0)
- Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry? (2023) (0)
- 1267 DISSECTING THE ROLE OF NRF2 IN NON-ALCOHOLIC LIVER STEATOSIS (2011) (0)
- In-vivo validation of cancer genes using liver organoids (2018) (0)
- RAGE is required for oval cell activation and inflammation-associated mouse liver carcinogenesis (2012) (0)
- Abstract No. 481 Chemosaturation with percutaneous hepatic perfusion in patients with metastasized uveal melanoma: assessment of therapy outcome and safety (2021) (0)
- LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes. (2018) (0)
- Variants APOE (rs429358) and TM6SF2 (rs187429064) confer risk to hepatocellular carcinoma (2021) (0)
- Abstract No. 37 LEAP-012 trial in progress: pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment (2021) (0)
- p21 regulates liver progenitor cell activation and hepatocarcinogenesis in inflammation-associated liver disease (2013) (0)
- P0243 : Role of S100A8/A9 in carcinogen-induced hepatocellular carcinoma onset and development (2015) (0)
- [Multimodality treatment for hepatocellular carcinoma]. (2010) (0)
- Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors (2023) (0)
- The PLATON pilot-study “Platform for analyzing targetable tumor mutations”: A PLATON network study. (2021) (0)
- Adjuvant therapy of biliary tract cancers (2023) (0)
- Activation of the novel FIR/FBP-1/stathmin pathway induces proliferation and migration in human hepatocarcinogenesis (2009) (0)
- Contents Vol. 31, 2015 (2015) (0)
- In vivo RNAi screening identified MKK4 as a new therapeutic target for the improvement of liver regeneration (2013) (0)
- Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study (2023) (0)
- [Immuno-oncology : No longer a need for interventional radiology?] (2020) (0)
- Perioperative chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone in gallbladder carcinoma or in front of radical resection in BTC: The phase III GAIN trial. (2021) (0)
- Contents Vol. 102, 2021 (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Arndt Vogel?
Arndt Vogel is affiliated with the following schools:
